AlzeCure Pharma has received approval from the regulatory authorities in Sweden to begin the next clinical phase I study (multiple ascending dose, MAD) with the candidate drug ACD856 focused on Alzheimer’s disease.
“This is a statement of strength that shows that AlzeCure continues to deliver according to plan,” says Martin Jönsson, CEO of AlzeCure Pharma. “Diseases with cognitive disorders, and especially Alzheimer’s disease, are areas with high need of new, more effective treatments and I am very much looking forward to the continued development of this important candidate drug.”
AlzeCure’s third clinical study with ACD856
The MAD Phase I study is AlzeCure’s third clinical study with ACD856, the lead candidate drug within the company’s NeuroRestore platform. ACD856 is being developed as a symptom-relieving treatment for disease states where the cognitive ability is impaired, such as in Alzheimer’s disease. The primary study goal is to evaluate ACD856’s tolerability and safety after repeated dosing, as well as to examine early signals on brain activity.
The substances in the NeuroRestore platform stimulate several important signaling pathways in the brain, which, among other things, leads to improved cognition. Preclinical studies have shown that AlzeCure’s candidate drugs strengthen the communication between nerve cells and improve cognitive ability including memory functions, the company states.